We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+26.04%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$456M
AUM Growth
+$96.8M
Cap. Flow
+$9.73M
Cap. Flow %
2.13%
Top 10 Hldgs %
99.35%
Holding
15
New
2
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$5.88M
2
SRRK icon
Scholar Rock
SRRK
+$2.69M
3
NUVB icon
Nuvation Bio
NUVB
+$1.14M
4
BBIO icon
BridgeBio Pharma
BBIO
+$1.05M

Top Sells

Rank Stock Value
1
ELEV
Elevation Oncology
ELEV
+$1.04M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.9B
$316M 69.29%
6,089,611
+21,486
+0.4% +$1.05M
VRNA
2
DELISTED
Verona Pharma
VRNA
$65.7M 14.39%
615,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$2.02B
$20.3M 4.44%
1,316,806
– –
NUVB icon
4
Nuvation Bio
NUVB
$2.02B
$11M 2.4%
2,960,659
+419,650
+17% +$1.14M
GLUE icon
5
Monte Rosa Therapeutics
GLUE
$2.07B
$10.9M 2.39%
1,472,331
– –
BCAX
6
Bicara Therapeutics
BCAX
$1.82B
$8.98M 1.97%
568,919
– –
CMPS
7
Compass Pathways
CMPS
$1.67B
$6.87M 1.5%
1,198,418
– –
BBOT
8
BridgeBio Oncology
BBOT
$686M
$6.54M 1.43%
+564,625
New +$5.88M
BMEA icon
9
Biomea Fusion
BMEA
$92.5M
$4.14M 0.91%
2,048,757
– –
SRRK icon
10
Scholar Rock
SRRK
$6.33B
$2.87M 0.63%
+77,031
New +$2.69M
CALC icon
11
CalciMedica
CALC
$11.6M
$1.6M 0.35%
521,114
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$793M
$825K 0.18%
434,455
– –
MRKR icon
13
Marker Therapeutics
MRKR
$21.8M
$290K 0.06%
325,370
– –
OKUR
14
OnKure Therapeutics
OKUR
$170M
$244K 0.05%
88,607
– –
ELEV
15
DELISTED
Elevation Oncology
ELEV
– –
-2,834,910
Closed -$1.04M

Similar funds

PCMC
Paragon Capital Management (Colorado) Denver, Colorado $476M AUM 23.92% 1-Year Est. Return
BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
JSC
Jackson Square Capital San Francisco, California $477M AUM 78.87% 1-Year Est. Return
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return

Aisling Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Aisling Capital Management held 15 positions worth $456M, up 27% from $360M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aisling Capital Management's Q3 2025 filing shows 2 new, 2 increased and 1 closed positions. Its largest new stake was BridgeBio Oncology: 564,625 shares worth $6.54M. The largest sale was Elevation Oncology, an estimated $1.04M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q3 2025 buy was BridgeBio Oncology: 564,625 shares worth $6.54M.
  • Aisling Capital Management added most to Nuvation Bio in Q3 2025, an estimated $1.14M increase.
  • Aisling Capital Management fully exited Elevation Oncology in Q3 2025, selling an estimated $1.04M.
  • Aisling Capital Management's ten largest holdings make up 99% of its $456M portfolio in Q3 2025.
  • Aisling Capital Management opened 2 new positions and closed 1 in Q3 2025.
  • Aisling Capital Management's portfolio value rose 27% quarter-over-quarter to $456M.

Based on Aisling Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.